Analysts Set Nuvectra Corp (NASDAQ:NVTR) Price Target at $10.67

Nuvectra Corp (NASDAQ:NVTR) has earned an average recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $10.67.

A number of equities research analysts have commented on the stock. ValuEngine upgraded shares of Nuvectra from a “hold” rating to a “buy” rating in a research note on Thursday, October 10th. Piper Jaffray Companies decreased their target price on shares of Nuvectra from $18.00 to $4.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. JMP Securities decreased their target price on shares of Nuvectra to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. They noted that the move was a valuation call. Finally, Zacks Investment Research cut shares of Nuvectra from a “buy” rating to a “hold” rating in a research note on Wednesday.

NASDAQ NVTR traded down $0.11 on Monday, reaching $1.57. 351,500 shares of the stock were exchanged, compared to its average volume of 420,900. Nuvectra has a one year low of $1.24 and a one year high of $22.08. The firm has a market capitalization of $29.52 million, a PE ratio of -0.49 and a beta of 0.70. The company’s 50-day simple moving average is $1.53 and its two-hundred day simple moving average is $3.62. The company has a current ratio of 4.86, a quick ratio of 4.42 and a debt-to-equity ratio of 0.58.

Nuvectra (NASDAQ:NVTR) last released its earnings results on Wednesday, July 31st. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. Nuvectra had a negative net margin of 99.08% and a negative return on equity of 58.23%. The company had revenue of $12.35 million for the quarter, compared to analysts’ expectations of $12.42 million. Sell-side analysts forecast that Nuvectra will post -2.44 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC bought a new stake in shares of Nuvectra during the third quarter valued at approximately $30,000. Acadian Asset Management LLC bought a new stake in shares of Nuvectra during the second quarter valued at approximately $35,000. SNS Financial Group LLC bought a new stake in shares of Nuvectra during the second quarter valued at approximately $36,000. Resources Investment Advisors LLC. bought a new stake in shares of Nuvectra during the second quarter valued at approximately $39,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Nuvectra by 1,431.1% during the second quarter. Tower Research Capital LLC TRC now owns 13,030 shares of the company’s stock valued at $44,000 after buying an additional 12,179 shares during the last quarter. Hedge funds and other institutional investors own 78.24% of the company’s stock.

About Nuvectra

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Further Reading: What is Considered a Good Return on Equity (ROE)?

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.